Mavyret Prior Authorization for Orthopedics: Streamlining Co-managed Patient Care

The Intersection of Mavyret and Orthopedic Patient Management

Orthopedic practices routinely manage patients with complex health profiles, where systemic conditions like chronic Hepatitis C can significantly influence treatment pathways for major joint replacement, spine surgery, or advanced imaging. While Mavyret is prescribed by gastroenterologists or infectious disease specialists for HCV, an orthopedic practice may need to coordinate or acknowledge its prior authorization status as part of a patient's overall pre-operative optimization or ongoing care plan. Unresolved HCV can impact surgical risk, anesthesia considerations, and post-operative recovery, making timely access to Mavyret critical for holistic patient management.

Mavyret Prior Authorization Requirements: A General Overview

Prior authorization for Mavyret typically focuses on confirming the diagnosis of chronic HCV infection and assessing disease severity. Payers generally require comprehensive documentation to validate medical necessity, which may include specific diagnostic test results and a history of prior treatments. Understanding these core requirements is essential for any practice involved in the patient's care, even if the primary responsibility for the drug PA lies with another specialty.

Key Documentation for Mavyret Prior Authorization

• Confirmation of chronic Hepatitis C virus infection (positive serology and HCV RNA viral load)
• HCV genotype and subtype determination
• Evidence of liver fibrosis or cirrhosis (e.g., FibroScan results, biopsy reports, or clinical assessment)
• Detailed history of prior HCV treatments and documented response or contraindications
• Attestation from the prescribing specialist (typically gastroenterology or infectious disease)

Navigating Comorbidity-Driven PA in Orthopedics

Orthopedic prior authorization is already complex, focusing on conservative-care trial documentation, BMI criteria for joint replacement, and appropriate-use criteria for advanced imaging. When systemic conditions like HCV are present, the overall patient health status can influence the approval of orthopedic procedures. Coordinating drug PAs alongside procedure PAs, especially for high-volume categories like CPT 27447 (TKA) or CPT 22612 (lumbar fusion), requires integrated workflows to prevent treatment delays and ensure comprehensive patient care.

Common Prior Authorization Denial Reasons for Mavyret in a Co-managed Context

• Incomplete diagnostic documentation, such as missing HCV genotype or viral load results
• Insufficient medical necessity based on payer-specific criteria for liver disease stage
• Lack of specialist attestation or prescription from a non-qualifying provider type
• Failure to document prior treatment history or adherence to step therapy protocols
• Administrative errors, including incorrect coding or submission of outdated forms

Klivira's Role in Integrated Prior Authorization Workflows

Klivira's platform is designed to manage complex prior authorization scenarios, including those involving multiple specialties and drug-specific PAs. By leveraging SMART on FHIR integration with EMRs, Klivira can aggregate patient data—from imaging history to lab results and medication lists—to support both orthopedic procedure PAs and the coordination of drug PAs like Mavyret. This capability streamlines the multi-step PA cascade, ensuring that all necessary documentation is compiled and routed correctly, whether to a specialty benefit-management vendor for imaging or directly to the payer for drug approval.